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This article is a call for action to the relevant stakeholders to improve access to care and treatment for patients
with rare diseases in the Asia-Pacific region by looking into three main areas: (a) developing legislative definitions to
confer enforceable protection, (b) creating or strengthening policies by objectively measuring the impact brought
about by rare diseases and establishing platforms to reach out to the rare disease community, and (c) fostering
collaboration across sectors and countries. It is hoped that these suggested actions can catalyze discussions and
progress in the region.
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Dear Editor,
Despite many healthcare improvements in the Asia-
Pacific region, patients with rare diseases are still falling
through the cracks. Many healthcare systems tend to
consider each rare disease no differently from other
more common diseases although these patients face a
greater risk of being marginalized [1,2]. Based on the
World Health Organization’s prevalence estimate, collect-
ively, rare diseases can affect 292 million people in the
Asia-Pacific region [3].
Faced with uneven access to care and treatment of rare
diseases, we wish to highlight (a) legal framework, (b)
healthcare policy, and (c) collaborations as the three
areas where rare disease patients in the region can bene-
fit most. We are aware that separate considerations may
be required for rare diseases that are treatable versus
those that are not. However, for this letter, we would like
to make a collective call for action for all types of rare
diseases.* Correspondence: phawhl@nus.edu.sg
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unless otherwise stated.Developing legal definitions for terms such as “orphan
drugs” and “rare disease” is pivotal to setting up legal
frameworks to protect the well-being of the rare disease
community. Looking to Taiwan, the Rare Disease Control
and Orphan Drug Act brings significant economic relief
to patients with genetic rare diseases through subsidies or
reimbursement [4]. Despite the power that legislation
wields, the long and arduous journey towards passing a
bill can prompt one to look for non-legislative alternatives.
Thailand stands out in the region because even without a
legislative framework for rare diseases or orphan drugs,
working definitions culminated in the inclusion of the
Orphan Drug List into the National Drug List in
2012 [5]. While the lack of a legislative framework
could still achieve some operative success, only the
law can confer enforceable protection uniformly across
the country, thus avoiding abrupt policy changes or post-
code lottery situations.
Policy-wise, reaching out and understanding the rare
disease community are primary steps to identifying inad-
equacies in existing systems. In Europe, the European
Organisation for Rare Diseases (EURORDIS) led a survey
program that lent many insights to the predicament of the
rare disease community [6], and has important implications
in policy formulation. Information-gathering initiatives liketd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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European Union Committee of Experts on Rare Diseases
(EUCERD) later established with a mandate to formulate
and implement activities in rare diseases [7] illustrates how
a multi-national cross-sector panel can organize and im-
plement rare disease initiatives. A ‘EUCERD’-equivalent for
the region can raise the awareness and commitment of
policy-makers to act. To reach out to the community, the
Taiwan Foundation for Rare Disorders represents patients
with rare diseases in Taiwan before the policy-makers [8],
showcasing a model suitable for smaller countries; in bigger
countries, the National Organization for Rare Disorders
presents another model as an alliance of individual patient
groups [9]. Pooling previously fragmented groups on a
national level can generate the much-needed awareness to
overcome the lack of political will.
For implementation, a coordinated and pragmatic
approach should be considered. As tackling rare diseases
is resource-intensive, concerted efforts should be chan-
neled to meet a need without duplication. To this, sev-
eral European countries have launched defined national
strategies on rare diseases [10]. Drawing from Europe’s
experience, the European Commission had been a vital
catalyst in elevating awareness and coordinating infor-
mation exchanges. These brought visibility to the rare
disease community on the policy table. The high-level
approach taken by the European Commission has galva-
nized policy-level support and a similar approach should
be considered in the Asia-Pacific region. Having a task-
force to champion this cause will be a useful starting
point.
Collaboration is key to advancing care for patients
with rare diseases. Funded by a technology grant, South
Korea’s Rare Disease Knowledge Base showcases suc-
cessful inter-agency collaboration by linking genetic,
clinical and administrative databases to mitigate mis-
diagnosis. To be acquainted with global developments
in rare diseases, platforms such as the Global Rare
Diseases Patient Registry Data Repository (GRDR) and
the International Rare Diseases Research Consortium
(IRDiRC) can be explored. Countries stand to benefit from
GRDR’s existing data elements and open-source patient
registry templates [11]. To facilitate the generation and
exchange of data, countries in the region should actively
contribute to existing registries [12], or consider starting
registries for diseases unique to the region. On the re-
search front, the IRDiRC links researchers and organiza-
tions investing in rare diseases research [13]. Of the 36
IRDiRC member organizations, only four were from
the Asia-Pacific region, highlighting opportunities for
the region to step up especially for diseases unique to
the region.
In conclusion, we have identified three areas that war-
rant attention and action from relevant stakeholders toimprove access to care and treatment for patients with
rare diseases in the Asia-Pacific region. Several initiatives
offer good examples to emulate but progress across the
region is variable and more can be done through devel-
oping legislative definitions, strengthening rare disease
policies, and fostering stronger collaboration.
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